Cipla Bullish For Future, Caps Speculation On Top-Level Departures
After a tough Q3, Cipla indicates that things are looking up as it readies to enter fiscal 2020, with both the US and India businesses shaping up well. The company also sought to dispel concerns around top level exits.
You may also be interested in...
Cipla rang in a “modest” Q2 and management has cautioned that coming quarters might see significant headwinds including the impact of a constrained funding environment on the tender business and US sanctions-related turbulence in some markets.
Cipla’s global head (operations) Raju Subramanyam is leaving the firm to pursue his own ambitions. The exit has resulted in an interesting portfolio rejig at the Mumbai-based firm, known for its generally clear manufacturing compliance record.
One "sizeable" respiratory inhalation launch in the US every year, starting next year, is what Cipla is targeting as it expands its global franchise in the segment, though a filing this year for generic Advair isn't likely. The Indian firm also expects to sew up multiple biosimilar deals targeted at key emerging markets.